Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

“Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths ” read the new headlines.1

Surprised?  Not really.

The US “war on cancer” was declared in 1971 by President Richard Nixon when he signed into law the National Cancer Act. It has been an overall failure: nearly 50 years later, more people are diagnosed with cancer and dying from the disease than ever before.  At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three will be diagnosed with cancer in the course of their life.

Money is not the real problem. Cancer is an industry worth billions of dollars: In 2014, the National Cancer Institute (NCI)  stated that the medical costs of cancer care were $125 billion, with a projected 39 percent increase to $173 billion by 2020.  Working with the self-fulfilling prediction that the cancer market will grow, not shrink, research money keeps going to the wrong places and to people interested in making more money through new patents than in finding a cure for cancer.
Actually, the cancer industry produces too much income to allow a cure to be found.

When Mirko Beljanski, PhD, biologist-biochemist who worked for over 30 years at the famous Pasteur Institute in Paris, started to entirely rethink the origin of cancer and find new solutions in order to develop molecules able to selectively block cancerous cell multiplication without killing healthy cells, he ran into major opposition. The conventional oncology community ostracized him, despite the fact that his theories on cancer were aimed at complementing chemotherapy and radiation, not replacing them. That did not prevent François Mitterrand in 1994, then President of France, to turn to Beljanski during his battle with an advanced prostate cancer. Against all predictions, Mitterrand’s health improved and he was able to complete his second term as President. Powerful people became infuriated because some natural alternative treatment had thwarted Mitterrand’s prognosis and thus robed them from the opportunity to seize power. So, when Mitterrand ultimately died about 18 months after he left office, the French government brutally shut down Beljanski’s laboratory and mercilessly persecuted him.

Thankfully, The Beljanski Foundation has grown to become a 501(c)(3) non-profit organization whose mission is to further Dr. Beljanski’s research within a network of high-profile research institutions around the world, including Columbia University Medical Center, the University of Kansas Medical Center and Cancer Treatment Centers of America®.

REFERENCE

1- https://endpts.com/merck-halts-enrollment-on-two-phiii-keytruda-studies-as-outside-monitors-flag-a-worrying-rate-of-deaths/